Xenova Group PLC (XNVA): Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results
10/19/2005 5:12:54 PM
SLOUGH, U.K., March 3, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced preliminary 12 month findings from the second Phase I trial of TA-NIC, the Company's therapeutic vaccine being developed for the treatment of nicotine addiction.A total of 60 subjects who smoked between 10 and 75 cigarettes a day were recruited into the trial, divided into three cohorts. Within each cohort of 20 smokers, 16 received the active vaccine and 4 received the placebo. The primary objectives of the study were to evaluate the safety, tolerability and immunogenicity vs. placebo of three doses of TA-NIC -- 50 ug, 250 ug and 1000 ug. The vaccine was administered by intramuscular injection at weeks 0, 2, 4, 6, 8 and 12 with a booster at 32 weeks.
Secondary objectives included recording the number of cigarettes smoked per day, determining the time to first cigarette and the time to relapse following a quit attempt at week 12 and if necessary another quit attempt at week 32. These quit rates were then assessed again after 12 months
|